Eli Lilly’s Alzheimer’s treatment approved in China
(This Dec. 17 story has been corrected to say that the EU regulator reversed its July decision in November to recommend approval for Biogen’s drug, Leqembi, in paragraph 8) (Reuters) – China’s medical regulator has approved Eli Lilly’s treatment for early Alzheimer’s, providing patients with another option after Eisai and Biogen’s Leqembi received approval in January, the company said late on Tuesday. China is the fourth major market in which the treatment, sold under the … Read more…